Non-medical Switching of Infliximab to CT-P13 Biosimilar in Inflammatory Bowel Disease: A Focus on the Definition of “Non-medical Switch”
Sign Up to like & getrecommendations! Published in 2020 at "Digestive Diseases and Sciences"
DOI: 10.1007/s10620-020-06423-y
Abstract: We read with great interest the recently published “Systematic Review: non-medical switching of Infliximab to CT-P13 in inflammatory bowel disease” [1]. The review included three randomized controlled trials and about forty observational studies, in which… read more here.
Keywords: infliximab p13; medical switch; medical switching; disease ... See more keywords
Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10092130
Abstract: Background: Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is characterized by chronic relapsing intestinal inflammation. There are few data on the efficacy and safety in clinical practice of infliximab (CT-P13) in subcutaneous… read more here.
Keywords: patients ibd; infliximab p13; clinical practice; treatment ... See more keywords